Scott Tagawa

Scott Tagawa
About Scott Tagawa

Dr. Tagawa earned a BS in Biology from Georgetown University and an MD degree from USC where he completed a Fellowship in Hematology and Oncology. He is currently an Assistant Professor of Medicine and Urology at the Weill Cornell Medical College.

J591 is a monoclonal antibody against prostate specific membrane antigen (PSMA), a molecule on the surface of prostate cancer cells. Studies using J591 linked to radioisotopes (radioimmunotherapy, RIT) have demonstrated safety and efficacy as well as the ability to target known sites of disease in metastatic prostate cancer. Dr. Tagawa will continue clinical investigations of J591 in patients with advanced prostate cancer to determine the dosage and optimal administration schedule required to effectively treat the disease.

Neil Bander, MD, a world leader in urologic oncology translational research and inventor of the J591 monoclonal antibody, and David Nanus, MD, professor at Weill Medical College of Cornell University and internationally recognized leader in the treatment and care of patients with all types of genitourinary cancers, will provide mentorship.

Award

The 2008 LeFrak Family – PCF Young Investigator Award

Scott Tagawa, MD

Weill Cornell Medical College – New York, NY